MS SB2858

Permits eligible patients with life-threatening or severely debilitating illnesses to access individualized investigational drugs, biological products, or devices (including gene therapy and neoantigen vaccines) based on genetic profiles, with written informed consent.

Prohibits state licensing boards and Medicare certification entities from revoking, suspending, or taking action against health care providers' licenses solely based on recommendations for patients to access investigational treatments.

Prohibits state officials and agents from blocking eligible patients' access to investigational drugs or devices; provides liability protections for manufacturers and providers complying in good faith with the act's terms.

Eliminates cost-sharing requirements (deductibles, coinsurance, copayments) for screening mammography, diagnostic breast examinations, and supplemental breast examinations furnished by group health plans and health insurance issuers.

Effective July 1, 2024; includes severability clause declaring the act would have passed even if individual provisions are found unconstitutional.